Kimball Electronics (KE) Q4 2025: Medical Revenue Up 5% as CMO Bets Drive Margin Focus
Kimball Electronics sharpened its medical focus in Q4, offsetting automotive and industrial softness with disciplined cost management and a clear pivot to higher-margin contract manufacturing opportunities. With a new Indianapolis facility coming online and sole-supplier wins in respiratory care, the company is positioning for medical-led growth despite a near-term sales dip in FY26. Investors should monitor execution on medical ramp and working capital initiatives as KE navigates a transition year with margin resilience and cash flow discipline.
Summary
- Medical Vertical Expansion: New facility and sole-supplier wins accelerate strategic shift toward higher-margin medical contract manufacturing.
- Cost Structure Realignment: SG&A reductions and inventory discipline support margin stability amid top-line declines in auto and industrial segments.
- Critical Transition Year Ahead: FY26 will test KE’s ability to offset lost automotive programs with medical growth and operational leverage.
Performance Analysis
Kimball Electronics closed Q4 2025 with sequential sales growth of 2% despite an 8% year-over-year decline excluding the divested automation, test, and measurement (AT&M) business. The medical segment, now 28% of total revenue, grew 5% year-over-year as a key customer resumed production post-FDA recall, with KE becoming the sole supplier for respiratory care final assembly. Automotive, KE’s largest segment at 48% of sales, dropped 13% year-over-year due to the loss of a major braking program, partially offset by new program ramps in Romania. Industrial remained pressured, down 12% excluding AT&M, reflecting continued weakness in North America and Europe.
Gross margin declined 50 basis points to 8% but improved sequentially, while SG&A expense fell 23% year-over-year, aided by divestitures and cost control. Operating income margin held steady at 5.2%, with absolute dollar growth for the third consecutive quarter. Working capital initiatives drove the sixth straight quarter of positive cash flow, reducing inventory by 19% year-over-year and cutting cash conversion days to a three-year low of 85.
- Medical Resurgence: Medical revenue growth was driven by a sole-source respiratory care program, supporting margin mix improvement.
- Automotive Contraction: Loss of the Reynosa braking program created a $60 million headwind, with partial offset from new European programs.
- Cost Discipline: SG&A as a percentage of sales improved to 2.8%, and inventory reduction released $23 million in cash in Q4 alone.
Despite top-line pressure, KE’s margin profile and cash flow remain resilient, setting up for a transition year with medical-led growth as the key strategic lever.
Executive Commentary
"Our balance sheet is now in a position of competitive strength with ample liquidity to weather an unpredictable environment while providing dry powder for opportunistic investments."
Rick Phillips, Chief Executive Officer
"We made substantial progress adjusting our cost structure to demand trends throughout the year. We improved our balance sheet with working capital initiatives and aligned the portfolio for future growth expectations."
Janet Kroon, Chief Financial Officer
Strategic Positioning
1. Medical CMO Platform Acceleration
Kimball is doubling down on contract manufacturing organization (CMO, outsourced device manufacturing) for medical devices, with a new 300,000 square foot Indianapolis facility opening in November. This site will enable expansion into cold chain management, complete device assembly, and precision plastics. Management sees capacity for “hundreds of millions of dollars” in incremental medical business, with the CFO noting potential “well in excess of half a billion.” Sole-source wins and blue-chip customer focus increase revenue stickiness and margin accretion potential, especially in high-complexity finished devices.
2. Portfolio Realignment and Cost Structure Reset
Following the AT&M divestiture and the closure of Tampa, KE has aggressively reduced SG&A and inventory, aligning its cost base to current demand. The company maintained SG&A below 3% of sales for all quarters in FY25, with further initiatives planned for working capital efficiency. This leaner structure is intended to support higher margins when top-line growth returns, particularly as medical volumes scale.
3. Automotive and Industrial: Managing Headwinds
Automotive remains challenged by the loss of a major braking program and softer EV steering demand. While new European programs offer some relief, the segment is expected to decline in FY26. Industrial is stabilizing in climate control but faces broad-based softness elsewhere. Management is exploring industrial adjacencies but has no new initiatives to announce. The company’s flexibility to pass through tariffs and shift production across its global network offers some protection against external shocks.
4. Margin Expansion Levers
Medical CMO is expected to be margin accretive, benefiting from automation investments and a shift toward higher-value assemblies. Management highlighted that as revenue grows, capacity utilization will drive incremental margin gains. KE’s FDA experience and capability to handle drug products differentiate its offering and could support further expansion in high-complexity, regulated device manufacturing.
Key Considerations
KE’s FY25 was defined by operational discipline and portfolio repositioning, setting the stage for medical-driven growth. The company’s ability to execute on this pivot, manage working capital, and ramp new programs will determine the pace of margin and revenue recovery.
Key Considerations:
- Medical Ramp Execution: Success of the Indianapolis facility and new program wins will be critical to offsetting automotive declines.
- Margin Sustainability: Margin resilience hinges on medical mix, automation, and further SG&A discipline as sales trough in FY26.
- Working Capital Initiatives: Continued focus on inventory and AR/AP management is unlocking cash and reducing financial risk.
- Capital Allocation: $50-60 million in FY26 CapEx is heavily weighted to medical, with additional share repurchases possible given strong liquidity.
- Automotive and Industrial Weakness: Persistent demand softness in these segments underscores the urgency of medical diversification.
Risks
KE faces execution risk in ramping medical programs, particularly as the new facility comes online and customer transitions consolidate. Automotive and industrial segments remain exposed to cyclical and program-specific volatility, while global supply chain and tariff uncertainties could disrupt cost structure or customer demand. Failure to achieve targeted working capital reductions or medical growth could pressure margins and cash generation in FY26.
Forward Outlook
For Q1 FY26, Kimball expects:
- Net sales in the range of $1.35 to $1.45 billion for FY26, representing a 2% to 9% decrease from FY25
- Adjusted operating income margin of 4.0% to 4.25%
- CapEx of $50 to $60 million, with $30 million allocated to the new Indianapolis facility
Management’s full-year guidance accounts for a $60 million headwind from lost automotive programs and the absence of a large, non-recurring medical inventory sale. Medical and industrial are expected to grow modestly, while automotive will decline, with margin structure steady versus FY25. Working capital and cash flow discipline remain top priorities.
- Medical CMO ramp and customer wins are expected to drive growth in FY27
- Margin improvement is anticipated as capacity utilization increases with future sales recovery
Takeaways
Kimball Electronics is executing a strategic shift toward medical CMO, leveraging operational discipline and a strengthened balance sheet to weather near-term top-line pressure and position for higher-margin growth.
- Medical Focus Drives Strategic Pivot: Sole-source wins and a new facility underpin the transition to higher-value, margin-accretive medical manufacturing.
- Cost and Cash Flow Discipline Provide Downside Protection: SG&A reductions and working capital improvements buffer the impact of automotive and industrial weakness.
- FY26 Is a Transition Year: Investors should watch medical ramp execution, margin stability, and cash conversion as leading indicators for FY27 growth inflection.
Conclusion
KE’s Q4 results validate its disciplined approach to portfolio management and cost control, with medical-led growth offering a credible path to margin expansion as automotive and industrial headwinds persist. FY26 will test the company’s execution, but operational and financial levers are in place for a return to profitable growth in FY27.
Industry Read-Through
Kimball’s medical pivot highlights a broader trend among EMS (electronics manufacturing services) players seeking higher-margin, regulated verticals to offset automotive and industrial cyclicality. Margin resilience and cash flow discipline are increasingly critical as OEMs rationalize supply chains and demand visibility remains low. Investors in the EMS and contract manufacturing sector should watch for similar strategic reallocations and working capital initiatives as the industry adapts to post-pandemic demand normalization and supply chain volatility.